The pharmaceutical industry has been on a roll these last few years. In 2021, fifty-five new drugs got approved by Food and Drug Administration (FDA). This year is not going slow either! The pharmaceutical industry is giving its all to introduce remarkable drugs this year turning 2022 into a center for breakthrough medicines. Here are a few drugs that we are anticipating!
1. Donanemab by Eli Lilly:
Donanemab is a drug for the treatment of Alzheimer’s developed by Eli Lilly and it is the most awaited drug of this year. It is a monoclonal antibody that acts on the beta-amyloid. The forecast suggests that the drug sale will peak in 2026 generating a revenue of 4.8 billion dollars for Eli Lilly. FDA approved the drug on an accelerated basis due to the biomarker evidence. Eli Lilly ran a comparison against Aduhlem, which was released last year. The comparison showed that Donanemab reduced the beta-amyloid plaques more than Aduhlem which might give it an edge in the market!
2. Tirzepatide by Eli Lilly:
Tirzepatide developed by Eli Lilly is a Diabetes drug that acts as a GLP-1 and GIP receptor agonist. The phase 3 trials of the drug showed better efficacy than insulin glargine through more reduction in glycated haemoglobin concentrations in diabetics with cardiovascular risk. The estimated sales of Tirzpatide till 2026 will generate a revenue of 4.9 billion dollars.
3. Gantenerumab by Roche:
Gantenerumab is again an Alzheimer’s drug developed by Roche. Currently, gantenerumab is under phase 3 trials and more results will appear in late 2022 but it is given Breakthrough Therapy Designation by FDA. estimated revenue generation for Roche through gantenerumab will be 2.5 billion dollars with Eli Lilly’s Donanemab taking the first spot in upcoming Alzheimer’s drugs.
4. Bardoxolone by Reata Pharmaceuticals:
Bardoxolone is developed for chronic kidney failure that occurs as a result of Alport Syndrome. Bardoxolone activates nuclear factor erythroid-related factor 2 which restores mitochondrial function, reduces oxidative stress, and inhibits inflammatory signals. As a result, inflammatory response and tissue fibrosis are attenuated. By 2026, the revenue generated by bardoxolone will amount to 2.2 billion dollars. The FDA issued a Complete Response Letter to the drug indicating that the current form of the drug needs some changes before approval.
5. Tezepelumab-ekko by AstraZeneca and Amgen:
Tezepelumab-ekko is a drug for asthma. It is a monoclonal antibody that works by decreasing the population of eosinophils that are associated with causing an allergic attack in asthma patients. It targets TSLP, which is a cytokine playing a major role in the inflammatory mechanism of asthma. In the clinical trials, the drug helped with the asthma of patients having low eosinophil white blood cells. The estimated revenue generation by tezepelumab-ekko by 2026 is 2 billion US dollars.
With new drugs and therapies on the horizon, the future of clinical treatment of various dangerous and chronic diseases seems bright. The clinical trials of the mentioned drugs have shown promise but how many of these drugs make it big time into the market and earn estimated revenues is yet to be unravelled.